Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1051/medsci/2023067 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Temporal lobe epilepsy with isolated amygdala enlargement: anatomo-electro-clinical features and long-term outcome.
J Neurol
January 2025
Epilepsy Unit - Sleep Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Background: Temporal lobe epilepsy with isolated amygdala enlargement (TLE-AE) still lacks a definite characterization and controversies exist.
Methods: We conducted a retrospective study identifying brain MRI scans with isolated AE between 2015 and 2021. We collected clinical and paraclinical data of patients with TLE-AE and evaluated the outcome.
Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort.
Nat Commun
December 2024
Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Article Synopsis
- Glioblastoma is described as immunologically "cold," making it resistant to solo immune-checkpoint inhibitors (ICI) like pembrolizumab, although neoadjuvant use may improve survival based on prior studies.
- A study involving 25 additional patients analyzed tumor tissue for gene signatures and found that neoadjuvant pembrolizumab led to decreased cancer proliferation genes and increased T-cell activity, indicating a specific response to this treatment.
- Despite observing these molecular changes, the study did not confirm an overall survival benefit from neoadjuvant pembrolizumab, suggesting that some patients may inherently resist ICI and may need additional therapies for effective treatment.
[Neoadjuvant therapy for resectable non-small cell lung cancer].
Pneumologie
January 2025
Thorakale Onkologie, Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Deutschland.
Treatment perspectives for non-small cell lung cancer (NSCLC) have been significantly expanded by the integration of immune checkpoint inhibitors into multimodal therapy concepts. Currently, combined, immune checkpoint-inhibitor-based therapy concepts are also advancing into early, resectable stages of NSCLC. Neoadjuvant and perioperative chemoimmunotherapy opened up a promising new preoperative treatment approach, but also raises some new questions and challenges.
View Article and Find Full Text PDFA hierarchically acidity-unlocking nanoSTING stimulant enables cascaded STING activation for potent innate and adaptive antitumor immunity.
Theranostics
September 2024
Department of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, 750002, China.
Article Synopsis
- Neoadjuvant chemotherapy (NAC) is essential for treating advanced cancers, but improving patient survival remains a challenge due to its limited effectiveness and issues with tumor recurrence after surgery.
- Researchers have developed a new treatment called AUG, a nanoSTING stimulant liposome, which activates the immune response to help shrink tumors before surgery and reduce the chance of cancer returning post-surgery.
- In tests, AUG demonstrated over 90% effectiveness in inhibiting tumor growth and reduced postoperative metastasis by 75% when used alongside immune checkpoint inhibitors, showcasing its potential as a promising neoadjuvant therapy.
Lessons from Post-Immunotherapy Tumor Tissues in Clinical Trials: How Can We Fuel the Tumor Microenvironment in Gliomas?
Vaccines (Basel)
August 2024
Department of Neurological Surgery, University of California, San Francisco, CA 94143, USA.
Despite recent advancements in cancer immunotherapy, many patients with gliomas and glioblastomas have yet to experience substantial therapeutic benefits. Modulating the tumor microenvironment (TME) of gliomas, which is typically "cold", is crucial for improving treatment outcomes. Clinical tumor specimens obtained post-immunotherapy provide invaluable insights.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!